Traduction de «submitted applications continues to » (Néerlandais → Français) :

It is also clear that the number of submitted applications continues to rise sharply compared with previous reference periods.
It is also clear that the number of submitted applications continues to rise sharply compared with previous reference periods.

Submitted applications Validated applications Applications in “Parking”system Finalised applications
Submitted applications Validated applications Applications in “Parking”system Finalised applications

Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.
Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.

Number of submitted applications - IN
Number of submitted applications - IN

Of the submitted applications, 95% were processed within the set time limits.
Of the submitted applications, 95% were processed within the set time limits.

For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.
For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.

Work is proceeding on adjusting the existing regulations in order to introduce administrative simplifications, such as the accelerated determination of the acceptability of submitted applications.
Work is proceeding on adjusting the existing regulations in order to introduce administrative simplifications, such as the accelerated determination of the acceptability of submitted applications.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

The vaccine Menveo for protection against four meningococcal meningitis serogroups was submitted in 2008 for US and EU approval and initial use from ages 11-55, with late-stage trials in infants continuing to support future submissions.
Menveo, un vaccin destiné à assurer une protection contre quatre sérogroupes de la méningite à méningocoques, a fait, en 2008, l'objet d'une demande d'autorisation aux Etats-Unis et dans l’UE pour son utilisation entre 11 et 55 ans.